The document discusses evaluating the cost-effectiveness of diagnostic tests through modeling. It provides an overview of how cost-effectiveness analyses are applied to determine if a diagnostic test represents value for money. The modeling requires estimating test accuracy, modeling patient outcomes for different test results, and calculating an incremental cost-effectiveness ratio to compare the new test to current practice. It provides an example of modeling different diagnostic strategies for deep vein thrombosis.
Eligibility for national screening programmes can be personalised according to individual risk in order to improve outcomes and reduce costs. Existing methods of economic evaluation can be adapted to identify risk thresholds and help optimise services. We describe the development of a decision model used to evaluate the cost-effectiveness of risk-based screening for diabetic retinopathy.
Author(s) and affiliation(s): Chris Sampson, Office of Health Economics Marilyn James, University of Nottingham David Whynes, University of Nottingham Antonio Eleuteri, University of Liverpool Simon Harding, University of Liverpool.
Conference/meeting: Health Technology Assessment International (HTAi) 2018
Location: Vancouver, Canada
Date: 03/06/2018
Technologies that enhance the precision and effect of therapies can make a critical contribution to ensuring value for money and improving patient care. Methods and processes for assessing value, however, still are imperfect. This presentation reviews the challenges and identifies some approaches for meeting them.
Eligibility for national screening programmes can be personalised according to individual risk in order to improve outcomes and reduce costs. Existing methods of economic evaluation can be adapted to identify risk thresholds and help optimise services. We describe the development of a decision model used to evaluate the cost-effectiveness of risk-based screening for diabetic retinopathy.
Author(s) and affiliation(s): Chris Sampson, Office of Health Economics Marilyn James, University of Nottingham David Whynes, University of Nottingham Antonio Eleuteri, University of Liverpool Simon Harding, University of Liverpool.
Conference/meeting: Health Technology Assessment International (HTAi) 2018
Location: Vancouver, Canada
Date: 03/06/2018
Technologies that enhance the precision and effect of therapies can make a critical contribution to ensuring value for money and improving patient care. Methods and processes for assessing value, however, still are imperfect. This presentation reviews the challenges and identifies some approaches for meeting them.
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...Office of Health Economics
This project seeks to elicit the public’s preferences for different features of a genomic test to sequence advanced solid cancer tumours. Understanding the relative preferences for various attributes of targeted testing are useful for determining the value of sequencing approaches, and informing technology adoption decisions. A discrete choice experiment (DCE) survey was designed to assess the preferences of members of the Australian general public for targeted sequencing in advanced cancer. The survey presented respondents with 12 questions in which they had to choose between two unlabelled tests (Test A and Test B). Tests were specified in terms of five attributes: time to receive the test result; cost of the test; likelihood that the test result will lead to a change in treatment; length of time health care professionals spend describing the test; and type of health care team who explains the test result. Respondents were sampled from an online panel and also completed questions related to demographic and socio-economic factors, experiences of cancer and familial history. We found that cost, timeliness, expertise/location and likeliness of changing treatment regimes were identified as attributes of genomic sequencing that are most valuable to a sample of the public. These results will ultimately be compared with the results of an ongoing DCE being conducted with patients with advanced cancer who are undergoing sequencing.
Author(s) and affiliation(s): Paula Lorgelly (OHE), Grace Hampson (OHE), James Buchanan (Oxford), Melissa Martyn (MGHA), Jayesh Desai (PeterMac), Clara Gaff (MGHA), and iPREDICT MGHA Flagship collaborators
Conference/meeting: EuHEA 2018
Location: Maastricht, the Netherlands
Date: 12/07/2018
In a research report by Berdud, M., Drummond, M. and Towse, A. (2018), a reasonable price for an orphan drug was established based on the proposition that rates of returns from investments in developing orphan drugs should be no greater than the industry average (for all drugs). At the 2018 EuHEA conference held in Maastricht, The Netherlands, 11-14 July, Mikel showed (i) how the reasonable price should be established and (ii) how NICE's cost-effectiveness threshold should be adjusted to ensure a reasonable price for an orphan drug. In slides results are discussed and conclusions showed too.
Author(s) and affiliation(s): Mikel Berdud, PhD (OHE); Prof. Mike Drummond (University of York); Prof. Adrian Towse (OHE)
Conference/meeting: EuHEA 2018
Location: Maastricht, The Netherlands
Date: 12/07/2018
Slides from the presentation on extrapolation from progression free survival to overall survival in oncology given at the 2017 HTAi Annual Meeting in Rome
Do EQ-5D-3L and EQ-5D-5L Capture the Same Changes in Quality of Life Over Tim...Office of Health Economics
The existence of important dissimilarities between EQ-5D-3L and EQ-5D-5L, both in terms of the health profiles and preference-based values, is a key topic in current research. This study compares the performance of the 3L and 5L versions of the EQ-5D in capturing changes in quality of life and the resulting impact on estimates of QALYs for a large cohort of cancer patients. Data were obtained from Cancer2015, a large-scale longitudinal cancer cohort study in Australia. Cancer 2015 enrols newly diagnosed, treatment-naïve cancer patients, who complete quality of life questionnaires at baseline, and at various follow-up points (approximately 3 and/or 6 months continuously). Genetic Matching techniques are used to construct a match comparison group of patients. Post-matching regression adjustment is also implemented to control for any remaining imbalances. For matched QLQ-C30 profiles, we compare 3L and 5L tariffs, as well as the magnitude of changes in quality of life at different points along the treatment trajectory of individuals. We pay special attention to the sensitivity of the measures, by exploring the impact of 3L vs 5L on larger changes in quality of life compared to smaller changes. Our analysis finds that improvements in HRQoL as measured by the QLU-C10D (which is derived from the condition specific EORTC QLQ-C30 instrument) appear to be associated with smaller changes in utility quantified by the 5L compared to the 3L. When HRQoL is deteriorating between observations then the 5L tariff is found to produce bigger utility losses. While the crosswalk (a) loses the increased sensitivity of the 5L (if it detects more change) but (b) it stretches out utility values across a larger range (the 3L range), and hence gains or losses are larger and more in line with the 3L tariffs.
Author(s) and affiliation(s): Paula Lorgelly (OHE), Patricia Cubi-Molla (OHE), Mark Pennington (King's College London), Richard Norman (Curtin)
Conference/meeting: EuHea 2018
Location: Maastricht, Netherlands
Date: 13/07/2018
EuroBioForum 2013 - Day 1 | Katherine PayneEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# MARKET PERSPECTIVES #
Towards market access for personalised medicines: opportunities and recommendations
Katherine Payne
Professor of Health Economics, Health Sciences - Economics, University of Manchester
Member EuroBioForum Strategic Advisory Board
=======================================
http://www.eurobioforum.eu
Getting evidence from economic evaluation into healthcare practicecheweb1
Seminar:Understanding the underutilisation of evidence from economic evaluations in healthcare: a mixed methods design. Speaker: Gregory Merlo, Australian Centre for Health Services Innovation (AusHSI), Queensland University of Technology, Brisbane, Australia.
Strategy to incorporate pharmacoeconomics into pharmacotherapy Ravi Kumar Yadav
Pharmacoeconomics of the health care intervention is equally important like the safety and efficacy of drug. The various strategies are available to incorporate pharmacoeconomics into pharmacotherapy. The most popular strategies for applying pharmacoeconomics to assess the value of pharmaceutical products and services include using the results of published pharmacoeconomic studies, building economic models, and conducting pharmacoeconomic research.
Strategies for Considerations Requirement Sample Size in Different Clinical T...IJMREMJournal
-------------------------------------------------------ABSTRACT ---------------------------------------------------
Usually the main problem face any investigation it how to determent a sample size, however, some
considerations required in sample size to conduct the efficacy and make realistic well-researched before began
study. This study aimed to determine the maximum possible sample size at different phases of clinical trials and
attempt to achieve the best accuracy of the results. To achieve that the maximum sample size in different phases
we found that the maximum sample size of phase I was (75) relies on largest response rate 20% and the minimal
clinically important difference (MCID) 15%, and because the participants are healthy often that means 15%
enough to show positive results of the transition to the second phase. for the phase II clinical trials; the
maximum sample size was (388) depend on the error 5% and largest response rate 50% when the response rate
should not be less than 20% according to the design used in this phase. Depend on the endpoint and hazard
ratio in phase III clinical trials when the probability of survival of the treatment group equal to median of the
probability of survival 50% we found that the maximum sample size (4796). For the phase IV the maximum
sample size in different phases of clinical trials does not affect whatever the large of the population size and
remains constant as large as possible size.
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...Office of Health Economics
This project seeks to elicit the public’s preferences for different features of a genomic test to sequence advanced solid cancer tumours. Understanding the relative preferences for various attributes of targeted testing are useful for determining the value of sequencing approaches, and informing technology adoption decisions. A discrete choice experiment (DCE) survey was designed to assess the preferences of members of the Australian general public for targeted sequencing in advanced cancer. The survey presented respondents with 12 questions in which they had to choose between two unlabelled tests (Test A and Test B). Tests were specified in terms of five attributes: time to receive the test result; cost of the test; likelihood that the test result will lead to a change in treatment; length of time health care professionals spend describing the test; and type of health care team who explains the test result. Respondents were sampled from an online panel and also completed questions related to demographic and socio-economic factors, experiences of cancer and familial history. We found that cost, timeliness, expertise/location and likeliness of changing treatment regimes were identified as attributes of genomic sequencing that are most valuable to a sample of the public. These results will ultimately be compared with the results of an ongoing DCE being conducted with patients with advanced cancer who are undergoing sequencing.
Author(s) and affiliation(s): Paula Lorgelly (OHE), Grace Hampson (OHE), James Buchanan (Oxford), Melissa Martyn (MGHA), Jayesh Desai (PeterMac), Clara Gaff (MGHA), and iPREDICT MGHA Flagship collaborators
Conference/meeting: EuHEA 2018
Location: Maastricht, the Netherlands
Date: 12/07/2018
In a research report by Berdud, M., Drummond, M. and Towse, A. (2018), a reasonable price for an orphan drug was established based on the proposition that rates of returns from investments in developing orphan drugs should be no greater than the industry average (for all drugs). At the 2018 EuHEA conference held in Maastricht, The Netherlands, 11-14 July, Mikel showed (i) how the reasonable price should be established and (ii) how NICE's cost-effectiveness threshold should be adjusted to ensure a reasonable price for an orphan drug. In slides results are discussed and conclusions showed too.
Author(s) and affiliation(s): Mikel Berdud, PhD (OHE); Prof. Mike Drummond (University of York); Prof. Adrian Towse (OHE)
Conference/meeting: EuHEA 2018
Location: Maastricht, The Netherlands
Date: 12/07/2018
Slides from the presentation on extrapolation from progression free survival to overall survival in oncology given at the 2017 HTAi Annual Meeting in Rome
Do EQ-5D-3L and EQ-5D-5L Capture the Same Changes in Quality of Life Over Tim...Office of Health Economics
The existence of important dissimilarities between EQ-5D-3L and EQ-5D-5L, both in terms of the health profiles and preference-based values, is a key topic in current research. This study compares the performance of the 3L and 5L versions of the EQ-5D in capturing changes in quality of life and the resulting impact on estimates of QALYs for a large cohort of cancer patients. Data were obtained from Cancer2015, a large-scale longitudinal cancer cohort study in Australia. Cancer 2015 enrols newly diagnosed, treatment-naïve cancer patients, who complete quality of life questionnaires at baseline, and at various follow-up points (approximately 3 and/or 6 months continuously). Genetic Matching techniques are used to construct a match comparison group of patients. Post-matching regression adjustment is also implemented to control for any remaining imbalances. For matched QLQ-C30 profiles, we compare 3L and 5L tariffs, as well as the magnitude of changes in quality of life at different points along the treatment trajectory of individuals. We pay special attention to the sensitivity of the measures, by exploring the impact of 3L vs 5L on larger changes in quality of life compared to smaller changes. Our analysis finds that improvements in HRQoL as measured by the QLU-C10D (which is derived from the condition specific EORTC QLQ-C30 instrument) appear to be associated with smaller changes in utility quantified by the 5L compared to the 3L. When HRQoL is deteriorating between observations then the 5L tariff is found to produce bigger utility losses. While the crosswalk (a) loses the increased sensitivity of the 5L (if it detects more change) but (b) it stretches out utility values across a larger range (the 3L range), and hence gains or losses are larger and more in line with the 3L tariffs.
Author(s) and affiliation(s): Paula Lorgelly (OHE), Patricia Cubi-Molla (OHE), Mark Pennington (King's College London), Richard Norman (Curtin)
Conference/meeting: EuHea 2018
Location: Maastricht, Netherlands
Date: 13/07/2018
EuroBioForum 2013 - Day 1 | Katherine PayneEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# MARKET PERSPECTIVES #
Towards market access for personalised medicines: opportunities and recommendations
Katherine Payne
Professor of Health Economics, Health Sciences - Economics, University of Manchester
Member EuroBioForum Strategic Advisory Board
=======================================
http://www.eurobioforum.eu
Getting evidence from economic evaluation into healthcare practicecheweb1
Seminar:Understanding the underutilisation of evidence from economic evaluations in healthcare: a mixed methods design. Speaker: Gregory Merlo, Australian Centre for Health Services Innovation (AusHSI), Queensland University of Technology, Brisbane, Australia.
Strategy to incorporate pharmacoeconomics into pharmacotherapy Ravi Kumar Yadav
Pharmacoeconomics of the health care intervention is equally important like the safety and efficacy of drug. The various strategies are available to incorporate pharmacoeconomics into pharmacotherapy. The most popular strategies for applying pharmacoeconomics to assess the value of pharmaceutical products and services include using the results of published pharmacoeconomic studies, building economic models, and conducting pharmacoeconomic research.
Strategies for Considerations Requirement Sample Size in Different Clinical T...IJMREMJournal
-------------------------------------------------------ABSTRACT ---------------------------------------------------
Usually the main problem face any investigation it how to determent a sample size, however, some
considerations required in sample size to conduct the efficacy and make realistic well-researched before began
study. This study aimed to determine the maximum possible sample size at different phases of clinical trials and
attempt to achieve the best accuracy of the results. To achieve that the maximum sample size in different phases
we found that the maximum sample size of phase I was (75) relies on largest response rate 20% and the minimal
clinically important difference (MCID) 15%, and because the participants are healthy often that means 15%
enough to show positive results of the transition to the second phase. for the phase II clinical trials; the
maximum sample size was (388) depend on the error 5% and largest response rate 50% when the response rate
should not be less than 20% according to the design used in this phase. Depend on the endpoint and hazard
ratio in phase III clinical trials when the probability of survival of the treatment group equal to median of the
probability of survival 50% we found that the maximum sample size (4796). For the phase IV the maximum
sample size in different phases of clinical trials does not affect whatever the large of the population size and
remains constant as large as possible size.
ABSTRACT
Objective: Stroke is one of the leading causes of death and disabilities worldwide. Cost-effectiveness analysis helps identify neglected opportunities
by highlighting interventions that are relatively inexpensive, yet have the potential to reduce the disease burden substantially. In India, there are
wide social and economic disparities. Socioeconomic environment influences occupation, lifestyle, and nutrition of social classes which in turn would
influence the prevalence and profile of stroke. By reduction of delays in access to hospital and improving provision of affordable treatments can
reduce morbidity and mortality in patients with stroke in India. This study is designed to measure and compare the costs (resources consumed) and
consequences (clinical, economic, and humanistic) of pharmaceutical products and services and their impact on individuals, healthcare systems and
society.
Methods: The purpose of this study is to analyze and conduct a cost-effectiveness analysis for the treatment of stroke in Guntur City Hospitals.
The patients were treated either with aspirin or clopidogrel. The health outcomes were measured using Modified Rankin Scale, A prominent risk
assessment scale for stroke. The pharmacoeconomic data were computed from the patient data collection forms.
Result: The incremental cost-effectiveness ratio of aspirin and clopidogrel were calculated to be Rs. 8046.2/year.
Conclusion: The study concludes that aspirin has the increased socioeconomic impact when compared to Clopidogrel and we can see that the earlier
therapy has supported discharge, home-based rehabilitation along with reduced hospital stay and hence preferable.
Keywords: Stroke, Pharmacoeconomics, Cost-effectiveness analysis, Aspirin, Clopidogrel, Incremental cost-effectiveness ratio.
Pre-ASCO Seminar: (Re)Defining Value in Cancer Care: Priorities for Patients, Providers, and Health Systems
Panel: International Experience with Health Technology Assessment (HTA) & Lessons for the United States,
This presentation explains the main features of medicines which will be developed and authorised via the adaptive pathways. It provides a definition of real world evidence and the caveats associated with the use and analysis of real world evidence in drug development.
A pulmonary embolism is a blood clot that blocks and stops blood flow to an artery in the lung. In most cases, the blood clot starts in a deep vein in the leg and travels to the lung. Rarely, the clot forms in a vein in another part of the body. When a blood clot forms in one or more of the deep veins in the body, it's called a deep vein thrombosis (DVT).
Because one or more clots block blood flow to the lungs, pulmonary embolism can be life-threatening. However, prompt treatment greatly reduces the risk of death. Taking measures to prevent blood clots in your legs will help protect you against pulmonary embolism.
The design and implementation of CDS tools should not only include careful consideration of their content and purpose, but their method of monitoring for success in terms of outcomes, functionality, and how they fit in the context of other CDS tools that are currently in place (see Section 5 for further details). However, formalized support and regulation for CDS is not abundantly common. In 2018, the US Food and Drug Administration offered a draft set of recommendations for CDS software (Food and Drug Administration 2018). Although not enacted into law, this type of oversight only proposes to cover certain types of CDS, but it is not yet fully defined what it would cover. Organizations such as the Health Information and Management Systems Society (HIMSS) and the American Medical Informatics Association (AMIA) have made comments on this draft, making apparent the need for further clarification by the FDA on what types of CDS will be effected. Due to a lack of current formalized regulation, CDS developers and implementers must be conscientious in assuring these tools are in fact functioning as intended and not unintentionally causing patient harm. Referring to the 5 rights and GUIDE checklist may be helpful.
There is often more than one way of doing something in healthcare.
For
example, there may be two different drugs that can be used to treat
depres sion, or two surgical techniques for the management of dysmenorrhoea.
Note that interventions may be compared against each other ( for example
antibiotic A against antibiotic B) or against a ' do nothing' scenario.
There are different ways in which we can choose one of these options.
We may
decide to pick the more effective surgical technique, or we may decide to
select the less costly antidepressant. Economic evalu ation is a generic term for
techniques that are used to identify, measure and value both the costs and the
outcomes of healthcare interventions. An economic evaluation is concerned
with identifying the differences in costs and outcomes between options. It can
be defined as a study that compares the costs and benefits of two or more
alternative interventions; so, the main components are costs and benefits
Presentation by David Wonderling, Head of Health Economics at National Guideline Centre, Royal College of Physicians and Lauren Ramjee, Senior Health Economist, Royal College of Physicians.
This workshop outlines the principles of health economic evaluation for the NHS.
Exploring LIS practitioner engagement with research: lessons from a UK case s...ScHARR HEDS
Poster presentation on the role of library and information professionals in resesarch by Helen Buckley Woods
https://www.shef.ac.uk/scharr/sections/heds/staff/woods_h
Tata Group Dials Taiwan for Its Chipmaking Ambition in Gujarat’s DholeraAvirahi City Dholera
The Tata Group, a titan of Indian industry, is making waves with its advanced talks with Taiwanese chipmakers Powerchip Semiconductor Manufacturing Corporation (PSMC) and UMC Group. The goal? Establishing a cutting-edge semiconductor fabrication unit (fab) in Dholera, Gujarat. This isn’t just any project; it’s a potential game changer for India’s chipmaking aspirations and a boon for investors seeking promising residential projects in dholera sir.
Visit : https://www.avirahi.com/blog/tata-group-dials-taiwan-for-its-chipmaking-ambition-in-gujarats-dholera/
Attending a job Interview for B1 and B2 Englsih learnersErika906060
It is a sample of an interview for a business english class for pre-intermediate and intermediate english students with emphasis on the speking ability.
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
Kseniya Leshchenko: Shared development support service model as the way to ma...Lviv Startup Club
Kseniya Leshchenko: Shared development support service model as the way to make small projects with small budgets profitable for the company (UA)
Kyiv PMDay 2024 Summer
Website – www.pmday.org
Youtube – https://www.youtube.com/startuplviv
FB – https://www.facebook.com/pmdayconference
Memorandum Of Association Constitution of Company.pptseri bangash
www.seribangash.com
A Memorandum of Association (MOA) is a legal document that outlines the fundamental principles and objectives upon which a company operates. It serves as the company's charter or constitution and defines the scope of its activities. Here's a detailed note on the MOA:
Contents of Memorandum of Association:
Name Clause: This clause states the name of the company, which should end with words like "Limited" or "Ltd." for a public limited company and "Private Limited" or "Pvt. Ltd." for a private limited company.
https://seribangash.com/article-of-association-is-legal-doc-of-company/
Registered Office Clause: It specifies the location where the company's registered office is situated. This office is where all official communications and notices are sent.
Objective Clause: This clause delineates the main objectives for which the company is formed. It's important to define these objectives clearly, as the company cannot undertake activities beyond those mentioned in this clause.
www.seribangash.com
Liability Clause: It outlines the extent of liability of the company's members. In the case of companies limited by shares, the liability of members is limited to the amount unpaid on their shares. For companies limited by guarantee, members' liability is limited to the amount they undertake to contribute if the company is wound up.
https://seribangash.com/promotors-is-person-conceived-formation-company/
Capital Clause: This clause specifies the authorized capital of the company, i.e., the maximum amount of share capital the company is authorized to issue. It also mentions the division of this capital into shares and their respective nominal value.
Association Clause: It simply states that the subscribers wish to form a company and agree to become members of it, in accordance with the terms of the MOA.
Importance of Memorandum of Association:
Legal Requirement: The MOA is a legal requirement for the formation of a company. It must be filed with the Registrar of Companies during the incorporation process.
Constitutional Document: It serves as the company's constitutional document, defining its scope, powers, and limitations.
Protection of Members: It protects the interests of the company's members by clearly defining the objectives and limiting their liability.
External Communication: It provides clarity to external parties, such as investors, creditors, and regulatory authorities, regarding the company's objectives and powers.
https://seribangash.com/difference-public-and-private-company-law/
Binding Authority: The company and its members are bound by the provisions of the MOA. Any action taken beyond its scope may be considered ultra vires (beyond the powers) of the company and therefore void.
Amendment of MOA:
While the MOA lays down the company's fundamental principles, it is not entirely immutable. It can be amended, but only under specific circumstances and in compliance with legal procedures. Amendments typically require shareholder
Premium MEAN Stack Development Solutions for Modern BusinessesSynapseIndia
Stay ahead of the curve with our premium MEAN Stack Development Solutions. Our expert developers utilize MongoDB, Express.js, AngularJS, and Node.js to create modern and responsive web applications. Trust us for cutting-edge solutions that drive your business growth and success.
Know more: https://www.synapseindia.com/technology/mean-stack-development-company.html
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
3.0 Project 2_ Developing My Brand Identity Kit.pptxtanyjahb
A personal brand exploration presentation summarizes an individual's unique qualities and goals, covering strengths, values, passions, and target audience. It helps individuals understand what makes them stand out, their desired image, and how they aim to achieve it.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
1. School of Health and Related Research (ScHARR) The University of Sheffield Regent Court 30 Regent Street Sheffield, S1 4DA Website: www.sheffield.ac.uk/scharr
5. Information resources Bayesian Statistics in Health Economics Evidence review and synthesis Health Economics and Outcomes Research Cost-effectiveness modelling to support Healthcare Decision Making Main Focus of Research Areas
13. Evaluating the cost-effectiveness of diagnostic tests Dr Matt Stevenson Reader in Health Technology Assessment; NICE Appraisal Committee Member; Contributor to the NICE Diagnostic Assessment Programme manual
14.
15. Cost-effectiveness analyses In the last 10 years there has a been a considerable increase in the importance of cost-effectiveness analyses. This was due to the relatively fixed budget and a combination of ageing populations and emerging expensive interventions. This has led to the formation of funding agencies in England and Wales, Scotland, Australia and Canada.
16. Does a diagnostic test represent value for money? Diagnostic tests with high prices may be cost-effective (i.e. a worthwhile use of a limited budget). Conversely, diagnostic tests with low prices may not be cost-effective. The ‘gold standard’ approach for determining whether the price of a diagnostic test is justified is through an economic evaluation, or cost-effectiveness analysis.
17. Cost-effectiveness analyses The goal of funding agencies is to provide the greatest amount of health for society within the budget, and thus opportunity cost is a key principle. That is, what health would be lost if money was diverted from one intervention in order to fund another. The process is typically to estimate the cost-effectiveness of an intervention through modelling, and comparing this result with a value assumed to represent opportunity cost.
18.
19. Methods for evaluating diagnostic tests There have been, for some time, clear methods guide for undertaking evaluation of pharmaceutical interventions. Recently NICE has set up a Diagnostic Assessment Programme which has issues an interim statement of the methods it expects to be followed in evaluating diagnostics. http://www.nice.org.uk/media/164/3C/DAPInterimMethodsStatementProgramme.pdf
20. Simplified Overview of the modelling required The following slides discuss the steps that would be required to generate an estimate of the cost-effectiveness of a diagnostic test (or series of diagnostic tests). The overview is a simplification. More detailed discussion is provided in the previously listed HTA reports (all free to download) and the Diagnostic Methods statement
21. Estimating Test Accuracy The sensitivity and specificity of a diagnostic test must be estimated. These values would be combined with the estimated prevalence of the condition being tested for, to form an expectation of the number of true positives, true negatives, false positives and false negatives generated by the diagnostic test.
22. Modelling the patient experience For each of the four groups defined, an estimation of the events that would occur to the patient must be modelled. These may differ due to underlying risks and the chosen medical management. The modelling would include factors such as the risks of mortality, risk of morbidity, length of stay within hospital, costs for initial and subsequent care, treatment-related adverse-events and the quality of life for patients in each potential health state.
23. Modelling the patient experience Ultimately, an estimation of the life years, quality adjusted life years (QALYs*) and costs can be attributed to each of the four groups. These can be weighted by the proportions in each group to form a total cost and total QALY for patients post diagnosis. The costs of the diagnostic tests performed are then added. * The QALY is a combination of life years and patient utility. A person living for 10 years at a utility of 0.5 would gain 5 QALYs; a person living for 4 years at a utility of 0.75 would gain 3 QALYs
24. Calculating an ICER* Assume that post diagnosis, an average patient was expected to gain 10 QALYs at a cost of £20,000 under current best practice. These values became 11 QALYs at a cost of £18,000 following a new diagnostic test, which costs £4,000 per patient. In this instance the increase in cost is £2,000 (£18,000 - £20,000 + £4,000) The increase in QALYs is 1. (11 – 10) * An Incremental Cost Effectiveness Ratio.
25. Calculating an ICER In this example, the ICER would be £2,000 per QALY gained (£2,000 / 1) This would be compared with an estimation of the cost of gaining a QALY in interventions that are likely to be replaced.* Thus if this were the result from a real technology appraisal the diagnostic test would be likely to be recommended for use. * NICE has estimated this to be in the region of £20,000-£30,000
26. Implications for diagnostic pricing Where a new diagnostic test has a large impact on mortality or on the utility of a patient, then the QALY gained over the current diagnostic will be greater. ICER = Δ Cost / Δ QALY Thus, for a constant ICER, such a test would be able to command a higher price than a test with a smaller QALY gain.
27. Sequences and subgroups Note that sequences of tests and only incorporating tests on a subgroup of the population are possible. The following slide shows the predicted optimal strategy for diagnosing whether a patient has deep vein thrombosis. The costs of diagnostic tests, the risks of death, morbidity, recurrence, treatment-related adverse-events and the costs of treating future events were all considered in the model.
32. Additional complications with evaluating diagnostic tests There are reasons why evaluating diagnostic tests are more difficult than evaluating pharmaceuticals. Due to time restrictions these will be mentioned very briefly under broad headings.
78. Costs State in the model Perspective NHS & PSS Societal Employer At work £0 £0 £0 1 wk to 6 months sick leave Cost of usual care and intervention incurred by NHS NHS & PSS costs + Employer costs - Transfer costs Cost of intervention incurred by employer + Cost of replacing employee + Production loss over friction period + Salary of replacement employee after friction period + Occupational sick pay + Employer’s NI contribution 6-12 months sick leave Cost of usual care Cost of usual care Occupational sick pay + Employer’s NI contribution 12 months+ sick leave Cost of usual care Cost of usual care
88. Public health modelling: lessons learned from a contraception case study Hazel Squires, Jim Chilcott, Nick Payne, Lindsay Blank, Monica Hernandez, Louise Guillaume ScHARR, University of Sheffield
111. The decision problem To evaluate the cost-effectiveness of high dose statins (atorvastatin 80mg/d, rosuvastatin 40mg/d & simvastatin 80mg/d) versus simvastatin 40mg/d in individuals with acute coronary syndrome.
201. Systematic reviews of relevant data Myfanwy Lloyd Jones Senior Research Fellow ScHARR, University of Sheffield Email: m.lloydjones@sheffield.ac.uk
228. Systematic reviews of relevant data Myfanwy Lloyd Jones Senior Research Fellow ScHARR, University of Sheffield Email: m.lloydjones@sheffield.ac.uk
229.
230.
231.
232.
233.
234.
235.
236.
237.
238.
239.
240. AUROCs from key studies: test vs liver biopsy Test Degree of fibrosis Study AUROC (95% CI) ELF ‘ Moderate/severe’ Rosenberg 0.94 (0.84-1.00) FibroTest F2-F4 Naveau 0.83 (0.81-0.87) Nguyen-Khac 0.79 (0.69-0.90) Cirrhosis (F4) Naveau 0.95 (0.94-0.96) Nguyen-Khac 0.84 (0.72-0.97) FibroScan Severe fibrosis (F3-F4) Kim 0.98 (0.94-1.02) Mueller 0.91 + 0.03 Nahon 0.94 (90-0.97) Nguyen-Khac 0.90 (0.82-0.97) Cirrhosis Kim 0.97 (0.93-1.01) Mueller 0.92 (0.87-0.97) Nahon 0.87 (0.81-0.93) Nguyen-Khac 0.94 (0.87-0.98)
241. Sensitivity and specificity: ELF Test (subgroup with ALD) Degree of fibrosis Study Threshold score Sensitivity Specificity ‘ Moderate/severe’ Rosenberg 0.087 100% 16.7% 0.431 93.3% 100%
256. Developing and testing condition-specific preference-based measures: Lessons learnt and policy implications John Brazier, Donna Rowen, Ifigeneia Mavranezouli, Aki Tsuchiya , Tracey Young, Yaling Yang, Michael Barkham
257.
258.
Editor's Notes
PDG & literature to derive
Switching from atorvastatin (10/20mg) to generic simvastatin (20/40mg) saves approx £1,000/patient over 5 years (Moon 2006) SEARCH
Scenario A: Adherence in clinical trials reported 80-90% - results represent cost-effectiveness for individuals who tolerate potent doses AND adhere to treatment Scenario B: Scenario C: assumed individuals who didn’t tolerate potent statins received simvastatin 40mg/d
For Scenario B, For Scenario A & C: All potent doses would be considered cost-effective For Scenario B: Rosuvastatin would be considered cost-effective, Simvastatin 80mg/d would not
Alcohol consumption (? within the last 2 months) affects the results of several of the tests used in ELF and FibroTest, and causes inflammation which influences FibroScan results. FibroMAX may be less affected as it combines FibroTest with additional tests for steatosis (SteatoTest), non-alcoholic steatohepatitis (NashTest), and severe alcoholic steatohepatitis (AshTest). In patients with risk factors for ALD, it simultaneously presents the FibroTest, SteatoTest and AshTest results. 42
Lack of clarity about numbers of patients with ALD; lack of independence of test manufacturer
Naveau: patients hospitalised for alcoholism or complications of cirrhosis; test accuracy (biopsy) (2005); survival at 5 and 10 years (2009) Nguyen-Khac 2008: patients requiring alcohol detoxification/rehabilitation; test accuracy (biopsy) – this is the only FT study which seems independent of the manufacturer Excluded Foucher 2006a: alcoholic patients (not further defined) because test accuracy (biopsy) in subset only, and criteria for biopsy not clear
Excluded Thabut 2003 HVPG comparison in patients with patients with chronic liver disease as data relating specifically to patients with ALD neither published nor available from study authors
Kim 2009: patients with ALD; test accuracy (biopsy) Mueller 2010: patients with ALD; test accuracy (biopsy) Nahon 2008: patients with suspected ALD; test accuracy (biopsy) Nguyen-Khac 2008: patients requiring alcohol detoxification/ rehabilitation; test accuracy (biopsy) Janssens 2010: patients requiring alcohol detoxification/ rehabilitation; test accuracy (biopsy, HPVG) assessed only in those with scores indicating severe fibrosis Melin 2005: patients treated for alcohol withdrawal; test accuracy (biopsy) only in subset with FS score >13 kPa Foucher 2006a: alcoholic patients (not further defined); test accuracy (biopsy) in subset only, criteria for biopsy not clear, therefore study excluded
Foucher 2006b excluded because population overlapped with 2006a
Key studies – ie the only study of ELF, even though it is only a subgroup analysis of a mixed population, and the studies of FibroTest and FibroScan which focused on patients with known or suspected ALD, and biopsied all patients.
Low threshold: high sensitivity (in this case, all patients with moderate/severe fibrosis have a positive test result – no false negatives) but low specificity (ie lot of patients without moderate/severe fibrosis have a positive result – false positives) High threshold: lower sensitivity (ie some patients with moderate/severe fibrosis have false negative test results) but high specificity (ie no patients without moderate/severe fibrosis have a positive result – no false positives)
Janssens found that the threshold scores recommended for Hepatitis C (9.6 kPa for F3-F4, and 12.5 kPa for F4) had a poor PPV in patients with ALD (65% for F3-F4) (presumably because of the effect of alcohol-related liver inflammation), so looked at the effect of different thresholds.
Alcoholic steatohepatitis: Mueller et al found that diagnostic accuracy improved when patients with laboratory signs of ASH (GOT >100 U/L) were excluded; exclusion of patients with mildly elevated GOT (>50 U/L) improved accuracy re F3-F4 fibrosis, but not cirrhosis alone) – the specificity is affected more than the sensitivity (ie fewer false positives)
Either the whole study population is unrepresentative because of the disease severity (eg recruited from patients already scheduled for biopsy) Or the whole population is more representative, but biopsy is only performed in the subset with a NILT result suggesting severe disease
Naveau et al follow-up study of FibroTest found that only 21% were abstinent during follow-up period; 50% not abstinent, 29% unknown. No indication what the impact of the test result was. Some evidence that the ELF test and FibroTest may have some prognostic value, but without information about post-test drinking habits this is open to confounding
There are two major problems relating to the use of liver biopsy as the reference standard to assess the diagnostic accuracy of non-invasive liver tests. The first is the fact that it is an imperfect reference standard, and the second relates to ethical issues.
Because of the level of AEs, it would not be ethical to biopsy the full range of people with suspected ALD, including those who are unlikely to have fibrosis. So, the evidence clusters towards one end of the range, and we have much more evidence of the accuracy of the non-invasive tests in correctly identifying people who have severe fibrosis than in correctly identifying people who don’t have severe fibrosis
Care and management of dementia increasing concern
This is the development process that the team in Sheffield have developed and applied to a range of condition specific measures to create a health state classification system that is subsequently valued using a preference elicitation technique such as TTO
Why EFA
This is the development process that the team in Sheffield have developed and applied to a range of condition specific measures to create a health state classification system that is subsequently valued using a preference elicitation technique such as TTO
Sample size for DEMQOL-U was larger as the classification system describes more states and had a larger selected study design. using the AFD Names and Numbers version 3.1.25 database ( AFD Software Limited, Ramsey, UK) . The sample was balanced to the UK population according to geo-demographic profiles.
in which respondents valued states from one of the classification systems determined using a card block system. Interviewers worked systematically through blocks; odd and even blocks contained DEMQOL-U and DEMQOL-Proxy-U states respectively. This approach was used to try and ensure that there were no systematic differences across the geo-demographic profiles of the samples for each classification system. and this was done to help familiarise them with the classification system as there are concerns that naming the condition can affect elicited utility values (8). Face to face interviews This rank task further familiarised respondents with the classification system and the health states to be later valued using time trade-off (TTO).
18 to 78 observations with 306 and worst states. The range of mean values was 0.954 to 0.184 One or more states with mean value lower than worst state. There were a large proportion of TTO values at 1 for both measures (26.9% for DEMQOL-U the distribution of the data was negatively skewed)
287 valued worst states. The range of mean values was 0.961 to 0.331 (smaller than DEMQOL) one state with mean value lower than the worst state two states with a mean value higher than the best state. These apparent contradictions are most likely observed due to the much smaller number of observations for some states in comparison to worst state and best state 28.8% of values at 1 and distribution negatively skewed
Predicted range similar to observed range
Predicted range similar to observed range
Condition-specific preference-based measures have been derived from existing measures for Asthma quality of life questionnaire, overactive bladder questionnaire, EORTC-QOQ-C30, Sexual quality of life questionnaire etc. We are also nearing completion of measures for common mental health problems, epilepsy, dementia (using both self-report and proxy-report measures), and diabetes. This involves 3 stages. Firstly dimensions and items are selected using a combination of psychometric, factor and Rasch analysis. Secondly a sample of health states are valued by members of the general population, using, say, the time trade-off valuation techniques (primary data collection). Thirdly values are modelled using regression analysis to produce utility values for every health state defined by the measure. We’ve recently completed an MRC/NIHR funded study examining the methodology of the process and the HTA report is forthcoming. We have developed a measure suitable for children aged 7-11 years, the CHU-9D. (Current utility weights are from adults but work is ongoing to obtain preference weightings from children). This measure is being used in many studies in UK and Australia. AMD project involved primary data collection of HUI, SF-6D, EQ-5D utility values from approx 1000 patients with AMD in order to estimate the relationship between visual acuity and the generic measures to populate a cost-effectiveness model. We have recently undertaken many reviews examining whether EQ-5D is appropriate (assessing validity, responsiveness) for a range of conditions including...
Condition-specific preference-based measures have been derived from existing measures for Asthma quality of life questionnaire, overactive bladder questionnaire, EORTC-QOQ-C30, Sexual quality of life questionnaire etc. We are also nearing completion of measures for common mental health problems, epilepsy, dementia (using both self-report and proxy-report measures), and diabetes. This involves 3 stages. Firstly dimensions and items are selected using a combination of psychometric, factor and Rasch analysis. Secondly a sample of health states are valued by members of the general population, using, say, the time trade-off valuation techniques (primary data collection). Thirdly values are modelled using regression analysis to produce utility values for every health state defined by the measure. We’ve recently completed an MRC/NIHR funded study examining the methodology of the process and the HTA report is forthcoming. We have developed a measure suitable for children aged 7-11 years, the CHU-9D. (Current utility weights are from adults but work is ongoing to obtain preference weightings from children). This measure is being used in many studies in UK and Australia. AMD project involved primary data collection of HUI, SF-6D, EQ-5D utility values from approx 1000 patients with AMD in order to estimate the relationship between visual acuity and the generic measures to populate a cost-effectiveness model. We have recently undertaken many reviews examining whether EQ-5D is appropriate (assessing validity, responsiveness) for a range of conditions including...
ADHD project involves (ongoing) primary data collection of patients with ADHD and is an observation study examining the wider effects of ADHD on the patient and the family. AMD project involved primary data collection of HUI, SF-6D, EQ-5D utility values from approx 1000 patients with AMD in order to estimate the relationship between visual acuity and the generic measures to populate a cost-effectiveness model. Can move beyond the NHS perspective to societal perspective and take into account wider effects such as carer and productivity effects. Are currently involved in research for DH on value based pricing, as this is going to be used in the UK from 2014 onwards... Literature reviews can also be used to obtain values from the literature for use in the cost-effectiveness model and we have also undertaken research looking at synthesising utility values from multiple sources.
Jigsaw method to find out about key types evidence Into 4 groups. Each of you is going to become an expert (in 10 mins) on a particular level of evidence. Going to give you some information relating to one type of evidence. Read through it and digest the key points. Try to establish a clear definition and the pros and cons of using this type of evidence. You are then going to get together with fellow experts . Your task is to teach your fellow group members about the evidence you have been resesearching. 3 mins to get them up to speed. Your fellow group members will help you to prepare the key facts for your 3 min teaching session. You will each get a turn in your groups to be the expert, teaching the other group members about your evidence. Aim at the end – all group members informed about the key sources of evidence in very short space of time. So, 10 mins to digest your information. Then 15 mins with your fellow experts to plan your feedback session Then return to your groups and take turns to teach each other. Group members need to listen attentively and ask questions if they are unclear. At end, we are going to ask each group to feedback on what they have learned.
Jigsaw method to find out about key types evidence Into 4 groups. Each of you is going to become an expert (in 10 mins) on a particular level of evidence. Going to give you some information relating to one type of evidence. Read through it and digest the key points. Try to establish a clear definition and the pros and cons of using this type of evidence. You are then going to get together with fellow experts . Your task is to teach your fellow group members about the evidence you have been resesearching. 3 mins to get them up to speed. Your fellow group members will help you to prepare the key facts for your 3 min teaching session. You will each get a turn in your groups to be the expert, teaching the other group members about your evidence. Aim at the end – all group members informed about the key sources of evidence in very short space of time. 10 mins to digest your information. Then 10 mins with your fellow experts to plan your feedback session Then return to your groups and take turns to teach each other. 3 minute teaching session each person Group members need to listen attentively and ask questions if they are unclear. At end, we are going to ask each group to feedback on what they have learned
Supporting the Health Researcher of the Future In addition to supporting the key roles of basic education and continuing professional development health libraries are increasingly occupying an essential position in providing support to those involved in health research. Whereas previously such a role involved stocking a few key journals in a discipline and providing access to a much wider selection of peer reviewed articles through well-utilised interlibrary loan networks the emphasis has now shifted to a service “beyond the library walls”. Indeed the challenge faced by many libraries is that of warding off increasing invisibility as researchers become accustomed to accessing resources from their own desktops. Faced with such a challenge what can a health library that aims to meet the needs of its research community seek to do? One possibility is to reengineer the library's presence through a range of tailored services and virtual resources. This presentation will describe how a health library can utilise free or low cost technologies to deliver a suite of services that are based around the needs of particular programmes, projects or even individual researchers. It will describe the activities of the School of Health and Related Research at the University of Sheffield in moving forward its research support services through the use of wikis, RSS feeds, blogs and portals. The team will share lessons learnt and pointers for any other libraries seeking to extend its outreach to health researchers beyond the four walls of the library.
Supporting the Health Researcher of the Future (30 mins) The Context of Research Support (5 mins) The Potential of Web 2.0 (5 mins) Some Examples of Good Practice (4 mins) What we are doing in ScHARR/Y&H (9 mins) The Way Forward? (2 mins) Questions (5 mins)
Are you all familiar with CCs? Basically bibliographies identifying the key books in Health Subject areas to help librarians in Collection Development - either when setting up a collection from scratch or to help prioritise budgets which in new era is particularly pertinent. The process in updating these had however become very timeconsuming: - Difficult for people to meet - Diffcult to get people to contribute. - It was felt that an online version was now needed. So in this presentation I'll take you through some of the and the issues we needed to address, Helen will explain her scoping of various Web 2.0 tools and how we piloted the use of Library Thing with the Mental Heath CC and then we'll do a live demonstration to try and entice you all to go away and contribute to the new Medical CC! Have to begin with a disclaimer - we are not experts in Web 2.0 technologies. I for one work in an NHS Trust where frustratingly anything innovative is often firewalled, So we will be deferring all technical queries at the end to Frank
Core Collections have a long and fruitful history - over 17 years MIWP developed and when the group was disbanded, HLG took on the role of updating these in partnership with Tomlinsons. But the process had become very timeconsuming. When the issue of revising the CCs at one HLG committee meeting with a call out for volunteers, there was a definite tumbleweed moment.. We therefore set up a working group to look at alternative ways of revising these
HELEN Idea of using Web 2.0 application Not actually one but 3 challenges Team across the country Resource would be richer with more contributors Felt a need for the final lists to be available online These challenges need different solutions - I'm going to look at the last two and how Library Thing provided a full or part solution.
Consider 2nd challenge Increasing collaboration - we needed to make it easier and quicker for people to suggest titles for the collection. Considered 3 tools
HELENE We decided to pilot the use of Library Thing with the Mental Health CC which was the smallest of the collections and also the one in most dire need of updating - the first edition had been published in 1999. It had been produced by one library service, so had had limited ... A Library was set up on LT with the data from the last edition for people to comment on. A briefing paper was sent out to librarians working in mental health via as many channels as possible and they were encourgaged toget clinicians and university lecturers in their areas involved. People were encouraged to comment on the books - w
We created a Mental Health collection on LT and loaded all the books from the last edition onto LT, Tomlinsons having checked for new edtions.
Each book was assigned a tag, or subject term, making it easier for people to select the specific subjects they were interested in focusing on. As I said, we sent out some publicity and guidance to mental heatlh librarians via as many communication channels as possibe (e-mail discussion lists, the PLCS scheme etc) and asked them to contribute by commenting on the books already on the system, either to endorse them or to suggest that they should be removed and to suggest new books. They were also encouraged to try to get health professionals and lecturers in their area to contribute.
Excellent feedback received, LT facilitated discussion - people in some cases arguing as to why a particular book should still be included despite its date for example. People commented on whether books were on reading lists, how popular they were with their users, etc.
The Mental Health CC was published in December 2009. The Nursing CC, which Lori Harvard has co-ordinated is literally hot off the press - collect your copy from Tomlinsons stand today if you haven't already. Lori was involved in the complilation of the 3rd and 4th edition - doing it through LibraryThing made it all so much easier.
And Online version is available - either via the HLG website where we have a read-only version of the Collection on LT or via a new website which Tomlinsons have produced.
If you do contribute, your name will be included in the printed version of the 6th ed.
Sign in
Please don't delete anything!
Please add a brief comment to explain why you think the book is important and your name.